Optimization of Postoperative Adjuvant Therapy for Cervical Cancer Based on MRD(Minimal Residual Disease)

• Status: Recruiting
• Trial end date: 2028-12-30
• Target enrollment: 0
• Participant gender: Female

Summary

This study is a prospective cohort clinical trial that aims to investigate the safety and efficacy of a combined chemoradiotherapy and immunotherapy treatment for early postoperative cervical cancer. Specifically, this study seeks to evaluate the ability of MRD-based screening to detect and monitor changes in MRD status at different stages of treatment, its potential for use in monitoring patient recurrence rates and in prognosis evaluation. In addition, this study will investigate the safety and effectiveness of chemoradiotherapy combined with immunotherapy as a postoperative adjuvant therapy for patients identified to be at risk of early cervical cancer based on MRD screening.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Suzhou Municipal Hospital

Criteria

Inclusion Criteria:

1. Patients with histopathological and clinical (FIGO 2018) stage ⅠB2 ~II A2 cervical cancer.

2. Above the age of 18.

3. General status: ECOG score 0-2.

4. Be able to understand the research scheme, voluntarily participate in the study, and sign the informed consent.

5. Good compliance, able to cooperate with the collection of specimens at each node and provide corresponding clinical information.

Exclusion Criteria:

1. Suffering from other malignant tumors.

2. Do not receive the specified treatment or change the treatment regimen before the disease progresses.

3. The study cannot be followed up according to the defined clinical follow-up period.

4. Unable to accept or provide CT or other designated therapeutic evaluation means.

5. Have an autoimmune disease.